{
  "id": 8413048419942734185,
  "name": "Smith and Coast - 2013 - The economic burden of antimicrobial resistance Why it is more serious than current studies suggest.grobid.tei.xml",
  "segments": [
    {
      "header": "Introduction",
      "content": "d transmission of resistance threatens to undermine many of these advances (3) . the paper highlights the 'temporal tension' between the burden observed in the present and that which may be predicted for the future ."
    },
    {
      "header": "A brief history of AMR",
      "content": "y be seen as essentially a reaction to the use of antimicrobial treatments . the process of natural selection encourages micro-organisms to adapt to environmental pressures . resistance is temporary or permanent, but there is concern that over time there is no reason to suspect that resistance will not occur ."
    },
    {
      "header": "The current situation",
      "content": "between 1983 and 1992, 30 new antibiotics were approved in the usa, but only seven have been approved since 2003 . between 1968 and 2000, no new classes of antimicrobial were discovered . there remain no new class candidates for gram-negative bacteria ."
    },
    {
      "header": "FIGURE 1: DRUG DISCOVERY",
      "content": "2004, only 1.6% of drugs in development by the world's 15 largest drug companies were antimicrobials . a recent report identifies only two new drugs under development, both of which are in the early stages when failure rates are high . there have been many options proposed and discussed to try to encourage greater research and development, but it has recently been voiced that \"the existing classes of antibiotics are probably the best we will ever have\" the incidence and spread of mdr-tb is of concern to both the"
    },
    {
      "header": "Current activities",
      "content": "k, the first antimicrobial resistance strategy, published in 2000, had three inter-related key elements . this has involved encouraging better diagnosis, medicine management and use of therapeutics . work has helped to strengthen surveillance, infection prevention and control ."
    },
    {
      "header": "Why these are not sufficient",
      "content": ". there are incentives for pharmaceutical companies to develop a new drug for which health systems will aim to restrict use and thus potential profits . this is particularly true within the current system for incentivising r&d into new therapies ."
    },
    {
      "header": "Evidence on current economic burden",
      "content": "qualitatively we know that treatment failure caused by amr contributes to increased costs of care associated with: additional investigations such as laboratory tests and x-ray examinations . additional sideeffects from more toxic treatments, which have to be managed; longer hospital stay; longer time off work; reduced quality of life and productivity . this is not including costs associated with surveillance and activities associated with trying to control resistance itself ."
    },
    {
      "header": "Updated literature review",
      "content": "view focused both on costs of amr and costeffectiveness of control strategies . it found a total of 43 studies, although 22 were categorised at high risk of bias and excluded from analysis . of the 21 remaining studies, most were from the usa and hospital based ."
    },
    {
      "header": "TABLE 1 SUMMARY OF COST DATA",
      "content": "dies listed in table 1 are consistent with previous reviews, indicating three key findings that appear robust to change over time . first, there are a vast range of figures, from less than \u00a35 to more than \u00a320,000 in reported additional costs per patient per episode for hospital costs, and anything up to around \u00a310 billion per year for full societal costs . most studies originate in the usa, but this degree of national dominance is still unusual ."
    },
    {
      "header": "The case of MRSA",
      "content": "versus mssa is a very wide range of costs . second, even at the high-end, the costs remain quite modest ."
    },
    {
      "header": "BOX 1: A CASE STUDY OF MRSA",
      "content": "vely low cost for mrsa is reflective of amr more generally . at approximately $55bn ($20bn health service) per year, amr still rates quite low in the league table of disease burden for the us ."
    },
    {
      "header": "TABLE 2: COMPARATIVE ECONOMIC BURDEN",
      "content": "based loosely on the 'incremental' cost related to the extra treatment of resistant over (actual or assumed) susceptible infection . these costs, broadly speaking, increase as we see multi-drug resistance emerge (such as in case of mdr-tb), but at present organisms that are mr remain relatively rare and often occur in isolated outbreaks . the highest costs are those where organisms are totally resistant, where no therapy is effective creating high service use and"
    },
    {
      "header": "Limits of assessing 'costs of resistance'",
      "content": "dard 'cost-of-illness' approach will not capture the true nature of the costs of amr for three reasons . first, consumption of an antimicrobial will contribute to organisms generating resistance to its effects, and thus other people will suffer from reduced effectiveness . second, that lower effectiveness will impact on the original consumer ."
    },
    {
      "header": "FIGURE 2: SIGMOIDAL DEVELOPMENT OF AMR",
      "content": "plication is that this uncertainty regarding current and future burden combined with discounting of future benefits means that strategies to reduce transmission are far more likely to appear cost-effective than strategies to control emergence . estimates of cost-of-illness tend not to focus on less direct costs associated with the impact of resistance on patient safety or public confidence in healthcare institutions ."
    },
    {
      "header": "BOX 2: CASE STUDY HIPS",
      "content": "ystem has changed fundamentally over the last 60 years . it is designed to treat chronic conditions, provide treatments on a short-term -often day-case -basis, and encourage prevention . removal of antimicrobials could mean soaring rates of post-operative infection, mortality and morbidity from what are currently considered trivial infections ."
    },
    {
      "header": "Conclusion",
      "content": "pivotal period where, if current trends continue, there could be highly significant costs to healthcare, and society more generally .effective antimicrobials therefore need rediscovering as a scarce -and largely nonrenewable -resource (3) . we need to pursue a path that does not place undue emphasis on current burdens and costs ."
    },
    {
      "header": "Reducing uncertainty and increasing knowledge of full health system impacts",
      "content": "know the current economic burden is relatively low compared with other problems . but we do not know to what extent the future burden will grow, or how quickly . we also don't know whether an increasing burden will give impetus to technological change outside the drug arena that might mitigate effects ."
    },
    {
      "header": "Developing better, more radical, incentive mechanisms",
      "content": "development of new antimicrobials, if new therapies are discovered then they need to be protected, and hence the use of them discouraged . new options are needed that discourage high levels of use whilst avoiding disincentives for private sector r&d into new therapies . compared with current estimates of costs of discovery to market, remain small ."
    },
    {
      "header": "Enhancing international activity",
      "content": "vity may be key to encouraging the development of new drugs and diagnostics to help control multi resistant bacteria . it may also be vital to research to increase understanding of resistance mechanisms, cost trajectories, and means of controlling resistance in the absence of new drug developments . a multi-pronged integrated uk strategy is under development ."
    },
    {
      "header": "Lessons from climate change",
      "content": ", as a policy target, shares many of the characteristics of climate change . both are global problems where the response differs across nations . for both antimicrobial resistance and climate change there is considerable inertia to the major, radical, change required to move from mitigation to prevention . there appears to be some differences, however ."
    },
    {
      "header": "BOX 2: CASE STUDY HIPS",
      "content": "problem facing any attempt to estimate the impact of removal of antimicrobial therapies is data from such a situation . in an attempt to think laterally, we therefore looked at information relating to amputation - another major surgery involving limbs -a proxy for what rates may have been pre-and post-antimicrobial discovery . we used this information together with current studies looking at the infection pathway for hip replacement to construct and suggest possible values for the flow of patients requiring hip replacement ."
    },
    {
      "header": "Search Process",
      "content": "bibliographic database searching on generic terminology initial searching of electronic databases utilised key terms taken from the earlier review . the search of databases was limited to web of science and medline and to searches on titles . specific terms included:"
    },
    {
      "header": "Stage 2/4: Citation searching",
      "content": "papers selected for review were scanned to identify any further papers . review papers identified through the review were also used in citation searching ."
    },
    {
      "header": "Stage 3: Further electronic bibliographic database searching relating to specific terminology",
      "content": "pirical papers identified in search 1 and key review papers indicated that there were clearly papers relating to evidence about the costs of resistance in relation to particular micro-organisms that were being missed because of the lack of specific terminology . instead, a second search aimed to focus on two of the most studied and potentially more serious current resistant infections: methicillin-resistant staphylococcus aureus and vancomycin-resistant enterococcus (vre)"
    },
    {
      "header": "Inclusion criteria",
      "content": "x inclusion criteria for the review . papers providing either (i) empirical evidence on the economic impact of antimicrobial resistance obtained through primary data collection . containing information on any length of stay, mortality, patient cost and/or societal cost that may be attributable to amr 3. for primary studies, inclusion of a control group of those with a susceptible infection."
    },
    {
      "header": "Identification of papers",
      "content": "papers in the stage 1 search were initially identified from abstracts obtained in the literature search . papers that were obtained were then read and a final decision was made on whether they should be included in the review ."
    },
    {
      "header": "Data extraction",
      "content": "dardised data extraction forms were utilised . the following data were extracted for each study . a"
    },
    {
      "header": "Findings",
      "content": ", the review identified 24 relevant papers . the findings are summarised in the report and table 1 provides details from the individual studies included."
    }
  ]
}
